Navigation Links
Micromet to Present at the 16th Annual NewsMakers in the Biotech Industry Conference on September 16, 2009
Date:9/15/2009

BETHESDA, Md., Sept. 15 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that its President and CEO, Dr. Christian Itin, will present at the 16th Annual NewsMakers in the Biotech Industry Conference on September 16, 2009 in New York City. A simultaneous webcast of the event will be available on the company's website at www.micromet-inc.com.

           Forum:    16th Annual NewsMakers in the Biotech Industry Conference
           Date:     Wednesday, September 16, 2009
           Time:     11:00 am to 11:25 am U.S. Eastern Time
           Place:    Millennium Broadway Hotel
                     New York City, New York
           Webcast:  www.micromet-inc.com

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. Micromet's collaboration partners include Sanofi-Aventis, Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risk
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... analysis of patented university inventions licensed to biotechnology ... to commercialization. To open these roadblocks, the researchers ... during the discovery stage could lead to faster ... frequently derived from discoveries made in university laboratories ... known during clinical trials, which have a high ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 High ... and apply the most complete climate and Earth ... demanding climate change issues. , Eight national laboratories, ... with the National Center for Atmospheric Research, four ... new effort. Other participating national laboratories include Argonne, ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Not long ... E&L studies should be performed late in the development ... known. But current regulatory trends suggest that, like many ... the rise. In recent years, multiple drug sponsors have ... or address specific questions during phase I/II. It’s not ...
(Date:8/20/2014)... Sofia, Bulgaria (PRWEB) August 20, 2014 ... was released today including improvements to the ... rates and connectors for Lucene, SOLR and Elasticsearch. ... change for this high performance triplestore – GraphDB™ ... organizations interested in deploying the only mature enterprise ...
Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4
... - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI , ... second quarter ended June 30, 2009. , "We were ... Medical Products business during the quarter, including continued acceleration ... said Dr. William Hunter, President and CEO of Angiotech. ...
... , , SEATTLE, Aug. ... reported recent achievements and financial results for the second quarter and ... "The second quarter of 2009 was a transforming quarter for the ... III data at the American Society of Clinical Oncology Annual Meeting ...
... , NEW YORK, Aug. 5 ... biopharmaceutical company focused on the acquisition, development and commercialization ... of life-threatening diseases, including renal disease and cancer (the ... ended June 30, 2009. , , ...
Cached Biology Technology:Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 2Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 3Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 4Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 5Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 6Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 7Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 8Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 9Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 10Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 11Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 12Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 13Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 14Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 15Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 16Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 17Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 18Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 19Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 20Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 21Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 22Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 23Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 24Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 25Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 26Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 27Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 28Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 2Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 3Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 4Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 5Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 6Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 7Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 3
(Date:8/20/2014)... approximately 3 million infants, a team of scientists across ... Massachusetts Medical School, have shown that newborn screening for ... public health newborn screening programs. Data from 11 newborn ... the Journal of the American Medical Association ... newborns is higher than previously thought and believed to ...
(Date:8/20/2014)... have suffered concussions ready to return to action? A ... school athletes who head back on the field with ... in their abilities to simultaneously walk and do simple ... in their balance and/or altered walking speed, was found ... had returned to activity in less than a month. ...
(Date:8/20/2014)... could one day be made out of cocoa, rice ... reporting. The novel process they developed and their results, ... and plastic waste problems, appear in the ACS journal ... and colleagues at the Italian Institute of Technology point ... its production reached 288 million tons worldwide, but its ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... the health of the world,s oceans down a rapid ... or perhaps ultimately reverse the catastrophic problems they are ... a professor of oceanography at Scripps Institution of Oceanography ... of the oceans and their ecological health. Publishing his ...
... A critical component of NASA,s Mars exploration program ... in-depth analysis, plans for which are detailed in ... peer-reviewed journal published by Mary Ann Liebert, Inc. ... www.liebertpub.com/ast In the published report entitled, ...
... newly developed robot capable of diving as deep ... has been successfully completed by scientists and engineers ... the University of Washington (UW). The vehicle ... for seafloor instruments that will be deployed in ...
Cached Biology News:Oceans on the precipice: Scripps scientist warns of mass extinctions and 'rise of slime' 2Oceans on the precipice: Scripps scientist warns of mass extinctions and 'rise of slime' 3Bringing Martian samples to Earth -- preparations outlined in journal Astrobiology 2Robot vehicle surveys deep sea off Pacific Northwest 2Robot vehicle surveys deep sea off Pacific Northwest 3
Mouse monoclonal [YPF19] to Yersinia pestis ( Abpromise for all tested applications)....
... extracts cytosolic proteins from mammalian ... their phosphorylation state. The reagent, ... Protein Extraction reagent, includes four ... with Western blotting, immunoprecipitations, and ...
... The features we add to WinList ... the product every day. Features like automatic ... are the result of good suggestions, thoughtful ... of the features you depend on are ...
Ubiquitin-like protein 4A (Ubiquitin-like protein GDX). [Source:Uniprot/SWISSPROT;Acc:P11441] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: